The Government of Kenya, through the Ministry of Health and the Pharmacy and Poisons Board (PPB), has launched investigations into the growing misuse of the diabetes drug Ozempic, which is being increasingly used for weight loss rather than its intended medical purpose.
Public Health and Professional Standards Principal Secretary Mary Muthoni raised the alarm over the widespread off-label use of the medication, expressing concern about the rising trend of individuals, especially public figures—using Ozempic primarily for slimming down.
“There are growing concerns about the mass misuse of the injection to lose weight, whereas that is not the primary purpose of the Ozempic injection,” she said.
The situation is being worsened by local celebrities and influencers who continue to publicize their weight loss journeys using Ozempic, fueling demand and encouraging unsupervised use of the drug.
What is Ozempic?
Ozempic, whose generic name is semaglutide, is a prescription medication developed to treat adults with type 2 diabetes. It is primarily used to help manage blood sugar levels, reduce the risk of kidney function decline in patients with chronic kidney disease (CKD), and lower the risk of major cardiovascular events such as heart attacks or strokes in individuals with diabetes and existing heart conditions, according to Drugs.com.
The drug works by activating GLP-1 receptors in the body, which stimulates insulin release, slows down the emptying of the stomach, and reduces sugar production in the liver. These combined effects help control blood sugar levels (HbA1c), extend the feeling of fullness, and reduce appetite—often resulting in weight loss as a secondary effect.
However, it is this side-effect that many are now exploiting, using the medication not for its medical intent but as a quick solution for weight loss.
The U.S. Food and Drug Administration (FDA) has approved Ozempic strictly for managing type 2 diabetes in adults. Its approved uses include improving blood sugar control, reducing the risk of cardiovascular complications, and slowing the progression of kidney disease. It is not approved for weight loss.
In light of the growing misuse, Kenyan health authorities have vowed to tighten regulation and educate the public on the proper use of Ozempic. Investigations are ongoing to determine the extent of off-label distribution and usage.
by dennis milimo
